# A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

> **NCT04358393** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 69 (estimated)

## Conditions studied

- AML
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- CMML
- Myelodysplastic Syndromes
- High-risk Myelodysplastic Syndrome
- MDS

## Interventions

- **DRUG:** APG-115
- **DRUG:** 5-azacitidine

## Key facts

- **NCT ID:** NCT04358393
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-04
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358393, "A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04358393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*